Category Archives: Kansas Stem Cells

What Services Does Kansas Regenerative Medicine Center Offer?

Stem Cells (SVF): We are an advanced, stand-alone stem cell therapy center offering Autologous Adipose (Fat) Derived Stem Cell Treatments. Autologous stem cells from a persons own fat are easy to harvest safely under local anesthesia and are abundant in quantities up to 2500 times those seen in bone marrow. We use the latest surgical equipment, cell counter and instruments such as the advanced Terason Usmart3200t Ultrasound, to help pinpoint the deployment of your stem cells. Learn more at Terason.com.

Platelet Rich Plasma (PRP):We offer Platelet Rich Plasma as a stand-alone procedure or to be used in conjunction with your stem cell deployment. PRP treatment recently gained widespread recognition in the sports world. Platelets function as a natural reservoir for growth factors that are essential to repair injured tissues. PRP activates tenocytes to proliferate quickly and produce collagen to help repair injured tendons, ligaments, cartilage, and muscles.

The Cell Surgical Network was founded nearly two years after the formation of the California Stem Cell Treatment Center (founded in 2010). Affiliate members like Kansas Regenerative Medicine Center are generally made up of teams of multidisciplinary physicians in order to best assess and provide care for our patients. The Cell Surgical Network and KRMC emphasizes quality and is highly committed to clinical research and the advancement of regenerative medicine.

Currently, KRMC and all affiliate members use the same sterile closed surgical procedure to process fat using a mini-liposuction procedure in order to isolate and implant a patients own source of regenerative cells on the same day. The source of the regenerative cells actually comes from stromal vascular fraction (SVF) a protein rich segment from processed adipose tissue. Stromal vascular fraction contains a mononuclear cell line (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important growth factors that facilitate the stem cell process and promote their activity. Our technology allows us to isolate high numbers of viable cells that we can deploy during the same surgical setting.

While vigilant about patient safety, we are also learning about which diseases respond best and which deployment methods are most effective. CSN employs a clinical research coordinator and an online database to collect valuable data from throughout the network of affiliates. Affiliates like KRMC have the opportunity to share not only their data, but their experiences, thus implementing higher levels of understanding and care.

As a physician of over 40 years, I continue to be amazed at the results I see using stem cell therapy.

Frank C. Lyons, MD MEDICAL DIRECTOR

Visit our site dedicated specifically for athletes mmastemcell.com >

Read more from the original source:

Stem Cell Therapy | Kansas RMC

Stem cell research has often been a topic of controversy, but much of this is due to a misunderstanding of where stem cells come from. While it is true that embryos do contain stem cells, they are certainly not the only source. In fact, modern researchers are narrowing their focus on adult stem cells primarily those obtained from umbilical cord blood, cord tissue, and to a lesser degree, bone marrow. On Monday, April 22nd, Kansas Governor Sam Brownback signed a bill establishing the nations first adult stem cell research center at Kansas University Medical Center.

The bill was sponsored by anti-abortion groups and heavily promoted by the conservative Family Research Council. The center would have a strict ban on embryonic stem cells, and will instead focus only on adult stem cells. There are currently many trials underway involving stem cells obtained from adult bone marrow, but many researchers feel that the most promising potential lies in the stem cells found in umbilical cord blood and tissue. In addition to being controversy free, these cells are also pain free to collect. Since this material is normally discarded as waste, the risk normally associated with a medical procedure is not present.

The opening of this new research center would be a major boost for Kansas University. Since it would be the first of its kind and since new discoveries are being made every year on possible uses, a research center devoted exclusively to using these cells could become a world leader in developing new treatments and therapies. In addition, the non-controversial nature of the research would make it much more likely to receive the funding needed for this type of research.

This facility could help usher in a new era of medicine, and perhaps even makecord blood bankinga routine practice. To learn more about stem cell research, or how you can have your childs cord blood stored,contact CorCellat -888-882-CORD(2673) or (702) 914-7250 for international calls.

Read the original:

Kansas to Build First US Stem Cell Research Center | CorCell

A primary and high-priority area of interest in the CVRI involves investigation of adult stem cell biology and therapy. A growing body of evidence supports the notion that transplantation of adult stem/progenitor cells can induce cardiac repair and improve left ventricular function and structure after myocardial infarction. The stem cell program in the CVRI conducts research to identify the optimal cell for this purpose and to enhance the outcomes via modification of cells before transplantation.

The major goals of the stem cell program are:

Relevant projects:

Mesenchymal stem cell therapy for infarct repair: Mesenchymal stem cells represent a rare population of primitive cells that reside in the bone marrow and participate in organ repair following injury. Injection of these cells after myocardial infarction can repair the heart and improve left ventricular function. These studies are broadly directed at improving the outcomes of MSC therapy for cardiac repair.

Wnt11 signaling in stem cell-induced cardiac repair: Wnt11 is a member of the 'wingless' family of glycoproteins that participate in various biological processes, including cellular proliferation, differentiation, and migration during development. The goal of this project is to delineate the role of Wnt11 signaling in differentiation of adult bone marrow cells and in cardiac repair.

Pretreatment of stem cells for greater cardiac differentiation: Our laboratory has extensive experience with the induction of cellular differentiation using various defined media. The primary goal of this project is to identify biological agents that will direct differentiation of adult stem/progenitors in cardiac lineages.

Investigators, trainees, and associates:

Last modified: Jul 21, 2016

The rest is here:

Stem cell program - University of Kansas Medical Center

Urology is one of the fieldsat the forefront of stem cell therapy research.

Interstitial Cystitis / Painful Bladder Syndrome

Millions of patients suffer from Interstitial Cystitis/Painful Bladder Syndrome. This severe and debilitating condition has historically been confused with other bladder pathology which must be ruled out, making IC difficult to diagnose. Currently, Interstitial Cystitis/PBS is defined as an unpleasant sensation, (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks duration, in the absence of infection or other identifiable causes. (2009 new American IC/PBS Guidelines). Although there are several theories to explain IC, the exact cause remains unclear. Many patients with IC have the biomarker APF (antiproliferative factor) in their urine, which inhibits bladder cell proliferation, making healing of the bladder lining much more difficult. Recent research indicates IC may be related to systemic neurosensitization and neuroinflammation that occurs within the bladder and in other organ systems. Regardless of the cause, the end result of IC is damage to the urothelium and bladder muscle that can run the spectrum from mild mucosal irritation to deep Hunners ulcers.

InterstitialCystitisandadiposederivedmesenchymalstemcells

Adipose derived adult (non-embryonic) mesenchymal stem cells are currently being investigated for use in degenerative conditions that result in damage to various organs and systems. These cells have the ability to seek out areas of injury and regeneration and assist in the repair of nerves, blood vessels, muscle, fat, cartilage, bone, and many other structures. These cells are naturally recruited by cytokines (SDF-1 stromal derived factor one, HGF hepatocyte growth factor, and platelets), to sites of inflammation, ischemia, hypoxia, or injury and they assist in the healing process either by directly forming needed cells or secreting chemical messengers that promote healing. Stem cells are mobilized naturally from bone marrow when the body is healing but they are also found dormant, but available, in human adipose tissue. These stem cells from fat are abundant in levels up to 2500 times greater than those found in bone marrow and research indicates that the fat derived stem cells have equivalent regeneration potential to the bone marrow cells. Also, stem cell treatment success appears to relate to the number of cells used and this gives adipose cells a significant potential advantage to regenerate human tissues. Mesenchymal stem cells have been used extensively around the world in the successful treatment of orthopedic, cardiac, pulmonary, and neurologic disease in both humans and veterinary models. We have evidence that adipose derived stem cells can differentiate into functional smooth muscle cells and, therefore, we think that bladder repair by stem cells may be possible in IC patients. A recent study in mice with bladder outlet obstruction demonstrated that florescent protein labeled MSCs (mesenchymal stem cells) injected intravenously into test subjects incorporated into bladder muscle resulting in decreased hypoxia, hypertrophy, and fibrosis and increased blood flow. Nine out of ten mice who received MSCs had improved bladder compliance.

We know that patients with IC demonstrate abnormal cell signaling and cytokine release. For this reason, we believe that stem cell treatment may be helpful for interstitial cystitis patients who exhibit mucosal and smooth muscular damage. We have developed a protocol to treat patients with IC of various stages with adipose derived stem cells. Our protocol uses high doses of stem cells injected intravenously and also intra-vesically (directly into the bladder lumen) and, in some cases, directly into trigger points in the pelvic floor. We have evidence that intravesical instillation of adipose derived stem cells into mice effectively shows morphological and phenotypic evidence of smooth muscle incorporation into the bladder wall three months after instillation.

Kansas Regenerative Medicine Center is using high dose autologous adipose derived stem cells for the investigational treatment of various degenerative diseases. The use of autologous cells ensures that the patients receive cells from only their own bodies. The technology to isolate the adipose derived stem cells has been obtained from Korea and is state of the art. All studies are patient funded and not approved by the FDA. We have initiated a pilot study to investigate the effectiveness of high dose adipose derived stem cells on interstitial cystitis. Only adult adipose derived stem cells are used, since embryonic stem cells have the potential to form rare tumors and have ethical considerations. The stem cells are obtained from a mini liposuction-like procedure performed under local anesthetic. Stem cells are isolated on site from the patients own fat and then deployed in our facility within 90 minutes. Regenerative healing naturally takes time and we do not expect immediate improvement in symptoms. Patients will be followed closely through our research registry and carefully collected data to help establish effectiveness of our treatment protocols.

See the original post:

Stem Cell Therapy for Urological Issues | Kansas RMC

Antonio Rodrigo Nogueira Retires

Antnio Rodrigo Nogueira was born in the town of ...

Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to damage, or congenital defects. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves. (Wikipedia).

These adult stem cells are known as progenitor cells. This means they remain dormant (do nothing) unless they witness some level of tissue injury. Its the tissue injury that turns them on. So, when a person has a degenerative type problem, the stem cells tend to go to that area of need and stimulate the healing process. Were still not sure if they simply change into the type of injured tissue needed for repair or if they send out signals that induces the repair by some other mechanism. Suffice it to say that there are multiple animal models and a plethora of human evidence that indicates these are significant reparative cells.

Stem cell therapy relies on the bodys own regenerative healing to occur. The regenerative process may take time, particularly with orthopedic patients, who may not see results for several months. In some diseases, more immediate responses are possible.

Originally posted here:
Kansas Regenerative Medicine Center

A recent discovery could increase older women's chances of having babies.

Karen Weintraub

May/June 2012

WHO Jonathan Tilly OvaScience, Boston

TECHNOLOGY Stem cells in ovarian tissue could form new eggs or be used to rejuvenate a womans existing eggs.

OTHER NOTABLE INNOVATORS

Evelyn Telfer University of Edinburgh, Scotland

David Albertini University of Kansas

Jonathan Tilly may have discovered a way to slow the ticking of women's biological clocks. In a paper published in March, the Harvard University reproductive biologist and his colleagues reported that women carry egg stem cells in their ovaries into adulthooda possible key to extending the age at which a woman might have a baby.

Today, a woman's fertility is limited by her total supply of eggs and by the diminished quality of those eggs as she reaches her 40s. Tilly's work with the stem cellscells that can differentiate, or develop into other kinds of cellscould address both issues. For one thing, it's possible that these newly discovered cells could be coaxed to develop into new eggs. And even if not, he says, they could be used to rejuvenate an older woman's existing eggs.

Tilly first found egg stem cells in mice in 2004. Once he identified egg stem cells in ovarian tissue from adult women, he isolated the cells and injected them into human ovary tissue that was then transplanted into mice. There the cells differentiated into human oocytes, the immature egg cells that mature, one at a time, at ovulation. Tilly didn't take these oocytes any further, but he says he has gotten egg stem cells from mice to generate functional mouse eggs that were fertilized and exhibited early embryonic development.

The research is still a long way from creating a crying human newborn. Nevertheless, the paper "changes what we understand" about fertility, says Tilly, who also directs a center for reproductive biology at Massachusetts General Hospital. Though some of Tilly's peers remain dubious that the cells he's found in women's ovarian tissue are actually stem cells or could become functional egg cells, many find the research provocative. "I think this is a very intriguing leap," says Elizabeth McGee, an associate professor and head of reproductive endocrinology and infertility at Virginia Commonwealth University. "However, I think there's still a long way to go before this becomes a useful product for women."

Boston-based OvaScience, which is commercializing Tilly's work, hopes it won't be too long. The company's cofounders include venture capitalist Christoph Westphal and Harvard antiaging researcher David Sinclair, who founded Sirtris Pharmaceuticals and sold it to GlaxoSmithKline for $720 million in 2008. OvaScience has raised $43 million to pursue fertility treatments and other applications for the stem cells.

One of the more tantalizing implications is that this technology could be used to reclaim the youth of an older woman's eggs. Tilly says he can do this by transferring mitochondriathe cell's power sourcefrom the stem-cell-derived cells into the existing eggs. Researchers who tried something similar in the 1990s, with the help of young donors, found that mitochondria from the donors' egg cells could improve the viability of older eggs. But the nearly 30 children who resulted from this work ended up with DNA from two women as well as their father. (It's not clear whether the children suffered any health consequences.) By being her own source for the younger mitochondria, a woman could avoid that potentially dangerous mix of DNA, Tilly says.

David Albertini, director of the Center for Reproductive Sciences at the University of Kansas Medical Center and a member of OvaScience's advisory board, says he "can't wait to get [his] hands on" Tilly's cells for his own egg research. But he says it's too soon to consider implanting them in women before much more testing is done in mice.

Read the original here:
Egg Stem Cells - MIT Technology Review

select a specialty Acupuncturist Addiction Medicine Adolescent Medicine Adult Care Aerospace Medicine Allergist Allergy & Immunology Alternative Ambulatory Care Anesthesiologist Audiologist Bariatrician Cardiac Electrophysiology Cardio Thoracic Surgeon Cardiologist Cardiovascular Disease Cardiovascular Surgeon Child Neurology Child Psychiatrist Chiropractor Clinical Laboratory Immunology Clinical Pathology Clinical Pharmacology Colon/Rectal Surgeon Community Health Critical Care Specialist Cytopathology Dermatologist Dermatopathology Diabetes Specialist Diagnostic Radiologist Emergency Medical Technician Emergency Medicine Specialist Endocrinologist Endovascular Surgical Neuroradiology Family Practitioner Gastroenterologist General Practitioner General Surgeon Genetics Specialist Geriatrician Gynecologic Oncologist Gynecologist Hand Surgeon Head & Neck Surgery Hematologist Hematology & Oncology Hepatologist Holistic Medicine Home Health Hospitalist Immunologist Infectious Disease Specialist Internal Medicine Internal Medicine/Pediatrics Interventional Cardiologist Legal Medicine Long Term Care Marriage & Family Therapist Massage Therapy Maternal Newborn Medical Oncologist Medical Toxicologist Naturopathic Medicine Neonatal Intensive Care Neonatologist Nephrologist Neurologist Neuroradiology Specialist Neurosurgeon Not Classified Nuclear Cardiology Nuclear Medicine Specialist Nutrition Obstetrics Obstetrics & Gynecology Occupational Medicine Spec Oncologist Ophthalmologist Optometrist Oral Surgeon Orthopedic Foot & Ankle Orthopedic Reconstructive Sgn Orthopedic Spine Surgeon Orthopedic Surgeon Osteopathic Physician Other Specialties Otolaryngologist Pain Management Specialist Palliative Medicine Pathologist Pediatric Allergist Pediatric Cardiology Pediatric Critical Care Pediatric Emergency Medicine Pediatric Endocrinology Pediatric Gastroenterology Pediatric Hematology/Oncology Pediatric Ophthalmologist Pediatric Pulmonology Pediatric Radiology Pediatric Surgeon Pediatrician Perinatal Physical Medicine/Rehab Specialist Plastic Surgeon Podiatrist Preventive Medicine Specialist Primary Care Psychiatrist Psychologist Pulmonary Critical Care Pulmonologist Radiation Oncologist Radiologist Reproductive Endocrinology Respiratory Therapist Rheumatologist Sleep Medicine Sports Medicine Specialist Surgical Oncologist Thoracic Surgeon Transplant Surgeon Trauma Surgeon Urgent Care Specialist Urologist Vascular & Interventional Radiology Vascular Surgeon Womens Health Specialist Wound Care

state AK AL AR AS AZ CA CO CT DC DE FL FM GA GU HI IA ID IL IN KS KY LA MA MD ME MH MI MN MO MP MS MT NC ND NE NH NJ NM NV NY OH OK OR PA PR PW RI SC SD TN TX UM UT VA VI VT WA WI WV WY

Follow this link:
Doctors in Kansas who treat or diagnose Stem Cell Transplant

SAN DIEGO. (Ivanhoe Newswire) -- According to the Christopher and Dana Reeve Foundation, nearly one in 50 people is living with paralysis. Until now, there wasn't much hope. But a new study involving stem cells has doctors and patients excited.

Two years ago, Brenda Guerra's life changed forever.

Guerra told Ivanhoe, They told me that I went into a ditch and was ejected out of the vehicle.

The accident left the 26-year-old paralyzed from the waist down, and confined to a wheelchair.

I don't feel any of my lower body at all she said.

Guerra has traveled from Kansas to UC San Diego to be the first patient to participate in a ground-breaking safety trial, testing stem cells for paralysis.

Joseph D. Ciacci, MD, Professor of Neurosurgery at UC San Diego told Ivanhoe, We are directly injecting the stem cells into the spine.

The stem cells come from fetal spinal cords. The idea is when they're transplanted they will develop into new neurons and bridge the gap created by the injury by replacing severed or lost nerve connections. They did that in animals and doctors are hoping for similar results in humans. The ultimate goal is to help people like Brenda walk again.

The ability to walk is obviously a big deal not only in quality of life issues, but it also affects your survival long-term Dr. Ciacci said.

Guerra received her injection and will be followed for five long years. She knows it's only a safety trial but she's hoping for the best

Read the original post:
Stem Cells for Paralysis: First of Its Kind Study

A downtown Topeka store will be honored as one of 16 businesses of the year by the Kansas Small Business Development Center.

The Merchant, 913 S. Kansas, sells used clothing, accessories, collectibles, art and books. Owner Lisa Boyd will be honored with the owners of the other 15 winning businesses Tuesday before the Kansas House of Representatives and Senate.

Each of the eight regional small business development centers was allowed to recognize an existing business that had been around for at least four years and an emerging one that had existed between two and four years.

Karl Klein, director of the Washburn University SBDC affiliate, said they chose Boyd as one of the winners for the region because of her commitment to her business and efforts to implement advice from the SBDC counselors she worked with, as well as her success continuing the business during construction that limited customer access on Kansas Avenue.

Its been a challenging environment and shes overcome a lot of those challenges, he said. I think theyve done well with attracting business.

Boyd said she started out renting a space in a building at 718 S. Kansas in 2009, and the Washburn University Small Business Development Center helped her develop her plans and get a loan in 2011 to buy the building where the business currently is located. The SBDC also helped with accounting questions as she learned on the job, she said.

I dont really look at it as Ive had challenges, she said. I just look at it as running a business and learning as I go.

The other winner for the region was Manhattan-based Kansas Regenerative Medicine, Klein said.

The clinic uses adult stem cells derived from a patients fat to attempt to treat degenerative diseases and was chosen because of its innovative concept, he said.

Kansas Regenerative Medicine is researching whether the therapy helps a variety of conditions, including joint problems, Parkinsons disease, strokes, lupus, Crohns disease and macular degeneration. The U.S. Food and Drug Administration hasnt approved that type of stem cell treatment for the conditions Kansas Regenerative Medicine is researching, so it cant make claims that the treatment will help, according to the businesss website.

See more here:
Topeka retailer honored as 'business of the year'

Kansas City, MO (PRWEB) February 09, 2015

One in five Americans will develop heart failure in their lifetime. It is the number one cause of hospitalization for adults over 65. The cost to treat heart failure is $32 billion and expected to double by 2030. There is no doubt heart failure is a significant health problem. The good news is proper care and treatment can dramatically improve a patients outcome and potentially promising new treatments are on the horizon.

February 8-14, 2015 is National Heart Failure Awareness Week. Saint Lukes Mid America Heart Institute, in Kansas City, Missouri specializes in treating heart failure and other complex cardiovascular conditions and has long been one of the leaders in cardiovascular care not only in the Midwest, but across the country.

Heart failure occurs when the heart is unable to efficiently move blood to the rest of the body either due to thickening or weakness. Onset can come from a variety of causes including heart attack, viral illness, abnormal heart valves, genetic traits and even after pregnancy. Symptoms can be subtle; shortness of breath, fatigue, dizziness, swelling in the legs and or stomach.

The good news is a variety of treatments are available and proper care and treatment can dramatically improve symptoms and quality of life for patients.

Treatments include:

The exciting news for patients is we have promising treatments currently in the research phase of development, said Bethany Austin, M.D., Associate Medical Director of the Advanced Heart Failure Program at Saint Lukes Mid America Heart Institute. These treatments range from clinical trials involving catheter based treatments, treatment of sleep apnea, and gene therapy with stem cells for damaged heart muscles. In addition, there is a new medication which has shown in recent trials to provide significant benefit to heart failure patients compared to standard therapy although it is not yet commercially available. All of these offer new hope to heart failure patients.

Saint Lukes offers a multidisciplinary heart team, including the regions only team of cardiologists board certified in Advanced Heart Failure and Cardiac Transplant, cardiothoracic surgeons, and critical care anesthesiologists.

The Saint Lukes Heart Failure Program also features:

In 2014, The Joint Commission awarded Saint Lukes Hospital Advanced Certification in Heart Failure. Only 53 other hospitals in the United States currently have Advanced Heart Failure Certification. Saint Lukes Hospital also received the Get With The GuidelinesHeart Failure Gold-Plus Quality Achievement Award for implementing specific quality improvement measures outlined by the American Heart Association/American College of Cardiology Foundation secondary prevention guidelines for heart failure patients.

See original here:
Saint Lukes Mid America Heart Institute Offers Tips & Treatments For Heart Failure Awareness Week 2015